- Markets
- Trading
- EVOQ
EVOQ
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Evoq Remedies Gets Show Cause Notice From SEBI
Dec 16 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES LTD - RECEIVES SHOW CAUSE NOTICE FROM SEBI
EVOQ REMEDIES LTD - NO PENALTIES OR FINES LEVIED IN SHOW CAUSE NOTICE
Source text: ID:nBSE6KWgDd
Further company coverage: EVOQ.BO
(([email protected];))
Dec 16 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES LTD - RECEIVES SHOW CAUSE NOTICE FROM SEBI
EVOQ REMEDIES LTD - NO PENALTIES OR FINES LEVIED IN SHOW CAUSE NOTICE
Source text: ID:nBSE6KWgDd
Further company coverage: EVOQ.BO
(([email protected];))
Evoq Remedies Appoints Bhumishth Narendrabhai Patel As MD
Aug 1 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
APPOINTS BHUMISHTH NARENDRABHAI PATEL AS MD
MD PAYAL BHUMISHTH PATEL RESIGNS
Source text for Eikon: ID:nBSE50cY3B
Further company coverage: EVOQ.BO
(([email protected];))
Aug 1 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
APPOINTS BHUMISHTH NARENDRABHAI PATEL AS MD
MD PAYAL BHUMISHTH PATEL RESIGNS
Source text for Eikon: ID:nBSE50cY3B
Further company coverage: EVOQ.BO
(([email protected];))
Evoq Remedies Approved Fund Raise Up To 226 Million Rupees
Jan 22 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
APPROVED FUND RAISE UP TO 226 MILLION RUPEES BY WAY OF ISSUE OF SHARES
FUND RAISE THROUGH PREFERENTIAL ALLOTMENT TO PERSON(S)/ ENTITY(IES) OF NON- PROMOTER CATEGORY
Further company coverage: EVOQ.BO
(([email protected];))
Jan 22 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
APPROVED FUND RAISE UP TO 226 MILLION RUPEES BY WAY OF ISSUE OF SHARES
FUND RAISE THROUGH PREFERENTIAL ALLOTMENT TO PERSON(S)/ ENTITY(IES) OF NON- PROMOTER CATEGORY
Further company coverage: EVOQ.BO
(([email protected];))
Evoq Remedies Gets Order Worth 1.36 Billion Rupees
Jan 10 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
GETS ORDER WORTH 1.36 BILLION RUPEES
Source text for Eikon: ID:nBSE40SGly
Further company coverage: EVOQ.BO
(([email protected];))
Jan 10 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
GETS ORDER WORTH 1.36 BILLION RUPEES
Source text for Eikon: ID:nBSE40SGly
Further company coverage: EVOQ.BO
(([email protected];))
Evoq Remedies Ltd- Resignation Of Dahyabhai Patel As MD
Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES LTD- RESIGNATION OF DAHYABHAI PATEL AS MD
EVOQ REMEDIES LTD- APPOINTMENT OF BHUMISHTH PATEL AS MD
Source text for Eikon: ID:nBSE2WR2vh
Further company coverage: EVOQ.BO
Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES LTD- RESIGNATION OF DAHYABHAI PATEL AS MD
EVOQ REMEDIES LTD- APPOINTMENT OF BHUMISHTH PATEL AS MD
Source text for Eikon: ID:nBSE2WR2vh
Further company coverage: EVOQ.BO
Evoq Remedies Appoints Dahyabhai Patel As MD
May 25 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES LTD - APPOINTS DAHYABHAI PATEL AS MD
Source text for Eikon: ID:nBSE8GZpQV
Further company coverage: EVOQ.BO
(([email protected];))
May 25 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES LTD - APPOINTS DAHYABHAI PATEL AS MD
Source text for Eikon: ID:nBSE8GZpQV
Further company coverage: EVOQ.BO
(([email protected];))
Evoq Remedies Says Bhumishth Patel Resigns As MD
March 31 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
BHUMISHTH PATEL RESIGNS AS MD
Source text for Eikon: ID:nBSE4tGmdb
Further company coverage: EVOQ.BO
(([email protected];))
March 31 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
BHUMISHTH PATEL RESIGNS AS MD
Source text for Eikon: ID:nBSE4tGmdb
Further company coverage: EVOQ.BO
(([email protected];))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does EVOQ Remedies do?
EVOQ Remedies Ltd. specializes in providing Pharmaceuticals Raw Material products, Excipients, and Bulk Drugs with a team of industry experts ensuring quality and affordability through certified manufacturers and importers.
Who are the competitors of EVOQ Remedies?
EVOQ Remedies major competitors are Dipna Pharma., Deccan Health Care, JFL Life Sciences, Ind-Swift, Biofil Chem & Pharma, Achyut Healthcare, Makers Laboratories. Market Cap of EVOQ Remedies is ₹8 Crs. While the median market cap of its peers are ₹71 Crs.
Is EVOQ Remedies financially stable compared to its competitors?
EVOQ Remedies seems to be less financially stable compared to its competitors. Altman Z score of EVOQ Remedies is 1.42 and is ranked 7 out of its 8 competitors.
Does EVOQ Remedies pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. EVOQ Remedies latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has EVOQ Remedies allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory, Short Term Loans & Advances
How strong is EVOQ Remedies balance sheet?
EVOQ Remedies balance sheet is weak and might have solvency issues
Is the profitablity of EVOQ Remedies improving?
The profit is oscillating. The profit of EVOQ Remedies is ₹0.45 Crs for Mar 2024, ₹1.62 Crs for Mar 2023 and ₹1.09 Crs for Mar 2022
Is the debt of EVOQ Remedies increasing or decreasing?
The debt of EVOQ Remedies is decreasing. Latest debt of EVOQ Remedies is -₹0.21 Crs as of Mar-25. This is less than Mar-24 when it was ₹4.05 Crs.
Is EVOQ Remedies stock expensive?
EVOQ Remedies is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of EVOQ Remedies is 86.87, while 3 year average PE is 24.0. Also latest EV/EBITDA of EVOQ Remedies is 0 while 3yr average is 5.63.
Has the share price of EVOQ Remedies grown faster than its competition?
EVOQ Remedies has given lower returns compared to its competitors. EVOQ Remedies has grown at ~-53.99% over the last 2yrs while peers have grown at a median rate of 15.04%
Is the promoter bullish about EVOQ Remedies?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in EVOQ Remedies is 11.21% and last quarter promoter holding is 11.21%.
Are mutual funds buying/selling EVOQ Remedies?
There is Insufficient data to gauge this.